To encourage the future development of biosimilars, policies need to both seek higher utilization of these drugs and support a sustainable market for these products, according to a study published in Frontiers in Pharmacology.1
“Besides complying with the same quality, efficacy, and safety standards as originator biologics, biosimilars often generate competition dynamics when entering the market, generally leading to lowered prices and savings,” investigators explained. “Global list price savings from biosimilars are expected to reach $285 billion, cumulatively in the period 2020 to 2025. This figure is likely to increase in the coming years, as biosimilar market shares expand and the economic impact of exclusivity losses for biologics rises. However, the level of competition generated by biosimilars varies according to the country’s biologics market, the care setting, and the…